• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

fMRI predicts benign brain tumors that turn malignant

Article

Perfusion-weighted MRI can anticipate the transformation of low-grade gliomas into malignant tumors up to a year earlier than other imaging tests, according to researchers. The technique could help select patients who may benefit from more aggressive treatment.

Perfusion-weighted MRI can anticipate the transformation of low-grade gliomas into malignant tumors up to a year earlier than other imaging tests, according to researchers. The technique could help select patients who may benefit from more aggressive treatment.

Adam Waldman, Ph.D., and colleagues at the Charing Cross Hospital in London prospectively enrolled 13 patients with low-grade gliomas for two years ending in August 2002. Patients underwent perfusion- and contrast-enhanced MRI every six months for up to three years to check for tumor malignancy. Investigators found that increases in blood volume by perfusion MRI suggested malignancy a year or more before it could be observed by contrast MR. They published their findings in the April issue of Radiology.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.